5th Zurich Brain Metastasis Symposium

Advances in systemic targeted therapy and immunotherapy have dramatically improved outcome at least in some types of solid cancer. However, metastasis to the central nervous system remains a major diagnostic and therapeutic challenge, notably in long-term survivors with cancers.


Grosser Hörsaal Ost USZ & hybrid




9.00 a.m. - 5.00 p.m.



Here we invite you to our 5th Zurich Brain Metastasis Symposium that will provide state-of-the-art presentations on current and future diagnostic and therapeutic approaches for patients with brain and leptomeningeal metastasis.


9.00 a.m. Welcome
Matthias Guckenberger, University Hospital Zurich
Michael Weller, University Hospital Zurich
Session 1: Isabell Witzel
9.10 a.m. Novel diagnostic approaches for CNS metastasis
Pieter Wesseling, Amsterdam University Medical Centers, Amsterdam and Princess Máxima Center for Pediatric Oncology, Utecht, The Netherlands
9.40 a.m. Where do we stand with liquid biopsy in CNS metastases?
Anna Bettina Sobottka-Brillout, University Hospital Zurich
10.10 a.m. Coffee Break
10.30 a.m. Insights into the proteomic landscape of brain metastases
Tobias Weiss, University Hospital Zurich
11.00 a.m. Markers of response or hyperprogression to immune checkpoint inhibition
Mitchell Levesque, University Hospital Zurich
Session 2: Nicolaus Andratschke
11.30 a.m. New Challenges and opportunities for neurosurgeons in the management of  brain metastasis
Marian Neidert, Cantonal Hospital St. Gallen
12.00 p.m. New challenges and opportunities for Radiation Oncology in the management of  brain metastasis
Giuseppe Minniti, University La Sapienza, Rome
12.30 p.m. Lunch Break
1.30 p.m. Controversies from the CNS Metastasis Guideline process: screening, timing of radiotherapy, intrathecal pharmacotherapy
Matthias Preusser, University Hospital Vienna
2.00 p.m. CNS trials at the Comprehensive Cancer Center Zurich
Emilie Le Rhun, University Hospital Zurich
2.15 p.m. Pharmacoscopy for CNS metastasis
Berend Snijder, ETH Zurich
Session 3: Andreas Wicki
2.30 p.m. Blood brain barrier and phrmacokinetic and phase 0 studies
Dieta Brandsma, Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam
3.00 p.m. Assessing response in CNS metastases trials: the RANO perspective
Lakshmi Nayak, Harvard University, Boston
3.30 p.m. Coffee Break
3.50 p.m. How to integrate brain metastasis into clinical trials: lessons from melanoma
Reinhard Dummer, University Hospital Zurich
Keynote Lecture: Michael Weller
4.20 p.m. Neoadjuvant immunotherapy: a perspective and a vision
Alexander Eggermont, Prinses Máxima Centrum voor Kinderoncologie, Utrecht
4.50 p.m. Wrap-up


Verantwortlicher Fachbereich